- Conditions
- Liver Fibrosis, Steatohepatitis, Elevated Transaminases
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- Not listed
- Lead sponsor
- UNC Nutrition Research Institute
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Kannapolis, North Carolina
- Conditions
- Acute Liver Failure, Mitochondrial Diseases, End Stage Liver Disease, Respiratory Chain Deficiencies, Mitochondrial, Disorder of Fatty Acid Oxidation
- Interventions
- Not listed
- Lead sponsor
- Arbor Research Collaborative for Health
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2029
- U.S. locations
- 15
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more
- Conditions
- Nonalcoholic Steatohepatitis (NASH)
- Interventions
- Firsocostat, Fenofibrate
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 5
- States / cities
- Tustin, California • Miami, Florida • Orlando, Florida + 2 more
- Conditions
- Liver Fibrosis Due to NASH
- Interventions
- Placebo, SIM
- Biological
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 259 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Coronado, California • San Diego, California + 35 more
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- Efimosfermin alfa
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Rialto, California • Tampa, Florida • San Antonio, Texas
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Interventions
- Miricorilant (Cohort A), Placebo (Cohort A), Miricorilant (Cohort B), Placebo (Cohort B)
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 48
- States / cities
- Chandler, Arizona • Tucson, Arizona • Huntington Park, California + 41 more
- Conditions
- Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes, Mitochondrial Metabolism Disorders
- Interventions
- Pioglitazone, Placebo
- Drug · Other
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- San Antonio, Texas
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- Placebo, ARI-3037MO
- Drug
- Lead sponsor
- Arisaph Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Familial Partial Lipodystrophy
- Interventions
- Obeticholic Acid, Placebo
- Drug
- Lead sponsor
- Abhimanyu Garg
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 2
- States / cities
- Dallas, Texas
- Conditions
- HIV Infections, Non-Alcoholic Fatty Liver Disease
- Interventions
- Semaglutide
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Baltimore, Maryland + 5 more
- Conditions
- Advanced Chronic Liver Disease, NASH
- Interventions
- VCTE with splenic stiffness measurement
- Device
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 298 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Non-alcoholic Fatty Liver Disease, Diabetes
- Interventions
- Dietary intervention (calorie restricted diet)
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Vallejo, California
- Conditions
- Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
- Interventions
- LY3849891, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 13
- States / cities
- Chandler, Arizona • Orange, California • Rialto, California + 8 more
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, NASH - Nonalcoholic Steatohepatitis
- Interventions
- Hepaxa
- Dietary Supplement
- Lead sponsor
- BASF AS
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Flowood, Mississippi
- Conditions
- Bariatric Surgery Candidate, Diet Modification
- Interventions
- Dietary modification with introduction of Mankai
- Other
- Lead sponsor
- Cleveland Clinic Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Weston, Florida
- Conditions
- Hepatic Steatosis
- Interventions
- Low glycemic load diet, Low fat diet
- Behavioral
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hepatic Steatosis
- Interventions
- VLX103
- Drug
- Lead sponsor
- Gyongyi Szabo
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Type 2 Diabetes, Hepatic Steatosis
- Interventions
- Magnetic Resonance Liver Assessment, Bike Exercise VO2max, DEXA
- Other
- Lead sponsor
- AdventHealth Translational Research Institute
- Other
- Eligibility
- 25 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, Steatosis of Liver
- Interventions
- Not listed
- Lead sponsor
- University of Oxford
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Cardiac Steatosis, Hepatic Steatosis
- Interventions
- Inspra /Eplerenone
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Non-alcoholic Fatty Liver Disease (NAFLD)
- Interventions
- Velacur
- Device
- Lead sponsor
- GI Alliance
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Flowood, Mississippi • Webster, Texas
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- MGL-3196, Placebo, Liver Biopsy
- Drug · Procedure
- Lead sponsor
- Madrigal Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,759 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 90
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 69 more
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC)
- Interventions
- Cilofexor
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 4
- States / cities
- Miami, Florida • Orlando, Florida • Knoxville, Tennessee + 1 more